
Rezolute RZLT
$ 3.12
-0.32%
Quarterly report 2025-Q4
added 02-12-2026
Rezolute Interest Expense 2011-2026 | RZLT
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Rezolute
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 375 K | - | 4.96 M | 689 K | 1.6 K | 5.04 K | 6.73 K | 4.23 M | 569 K | - | 204 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.96 M | 1.6 K | 1.23 M |
Quarterly Interest Expense Rezolute
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.8 K | 1.29 M | 911 K | 1.29 M | 912 K | 147 | - | 147 | - | - | 1.6 K | - | 1.6 K | 1.38 K | 1.61 K | 1.38 K | 1.61 K | 2.3 K | 500 | 2.3 K | 500 | 623 K | 165 K | 623 K | 165 K | 109 K | 105 K | - | 91.7 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 M | 147 | 264 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Ascendis Pharma A/S
ASND
|
80.6 M | $ 229.25 | 0.44 % | $ 5 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
AbbVie
ABBV
|
2.89 B | $ 208.84 | -2.86 % | $ 369 B | ||
|
AbCellera Biologics
ABCL
|
-2.71 M | $ 3.52 | 0.28 % | $ 1.05 B | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
72.4 M | $ 3.33 | -2.06 % | $ 99 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
11.8 M | $ 14.81 | 2.63 % | $ 2.25 B | ||
|
Altimmune
ALT
|
-190 K | $ 3.34 | 7.05 % | $ 294 M | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 91.18 | 1.97 % | $ 27.2 B | ||
|
ANI Pharmaceuticals
ANIP
|
-4.03 M | $ 74.21 | -2.3 % | $ 1.43 B | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
10.1 M | $ 8.03 | 2.29 % | $ 220 M | ||
|
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.41 | 2.17 % | $ 375 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.68 | 1.52 % | $ 16.8 M | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
59.3 M | $ 9.02 | -3.84 % | $ 1.86 B | ||
|
Axcella Health
AXLA
|
3.02 M | - | -16.42 % | $ 249 M | ||
|
Axon Enterprise
AXON
|
286 M | $ 412.81 | -2.54 % | $ 31.3 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
5.2 M | $ 318.85 | -3.01 % | $ 41.8 B |